AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.085

-0.025-22.73%

Volume:1.64M

Turnover:143.39K

Market Cap:45.45M

PE:-2.50

High:0.090

Open:0.090

Low:0.084

Close:0.110

52wk High:0.185

52wk Low:0.084

Shares:534.71M

Float Shares:351.37M

Volume Ratio:26.33

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.034

EPS(LYR):-0.034

ROE:-254.33%

ROA:-136.74%

PB:16.11

PE(LYR):-2.50

Loading ...

Overview Company News Filings

Securities Trading Policy-GDR

Constitution-GDR

Golden Dragon Mining Ltd FY2023 Audited Accounts-GDR

Neurizon Therapeutics Ltd-Replacement Prospectus-Gdr

THOMSON REUTERS

Replacement Prospectus-GDR

Information Form and Checklist-GDR

Appendix 1A-GDR

ASX Market Announcement - Admission and Quotation-GDR

Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment

MT Newswires Live

Neurizon Therapeutics Ltd-Quarterly Shareholder Update Webinar - Q1 FY2026

THOMSON REUTERS

BRIEF-FDA Lifts Clinical Hold On Nuz-001

Neurizon Therapeutics Ltd: Clears Way for Entry Into Healey ALS Platform Trial Expected to Commence in Q4 Cy2025

THOMSON REUTERS

BUZZ-Neurizon Therapeutics rises after US FDA lifts clinical hold on key therapy

Neurizon Therapeutics Ltd - U.S. FDA Lifts Clinical Hold on Nuz-001

THOMSON REUTERS

Neurizon Therapeutics' (ASX:NUZ) growing losses don't faze investors as the stock spikes 12% this past week

Simply Wall St.

Neurizon Therapeutics Secures AU$5 Million Through Share Placement

MT Newswires Live

Neurizon Therapeutics - Raises a$5 Mln via Institutional Placement at a$0.12 per Share

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Seeks Trading Halt

BRIEF-Neurizon Therapeutics Posts Loss For Year Attributable A$16.6 Million

Neurizon Therapeutics - Loss for Year Attributable a$16.6 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NUZ.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.085,"timestamp":1766466720000,"preClose":0.11,"halted":0,"volume":1642478,"delay":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":534705765,"eps":-0.034045,"marketStatus":"Closed","change":-0.025,"latestTime":"12-23 16:12:00 AEDT","open":0.09,"high":0.09,"low":0.084,"amount":143388,"amplitude":0.054545,"askPrice":0.088,"askSize":15562,"bidPrice":0.085,"bidSize":36729,"shortable":3,"etf":0,"ttmEps":-0.034045,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.11,"openAndCloseTimeList":[[1766444400000,1766466000000]],"volumeRatio":26.326994,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-136.74%","roe":"-254.33%","lyrEps":-0.034045,"volumeRatio":26.326994,"shares":534705765,"dividePrice":0,"high":0.09,"amplitude":0.054545,"preClose":0.11,"low":0.084,"week52Low":0.084,"pbRate":"16.11","psRate":"29.55","week52High":0.185,"institutionHeld":0,"latestPrice":0.085,"committee":0.404792,"eps":-0.034045,"divideRate":0,"volume":1642478,"delay":0,"ttmEps":-0.034045,"open":0.09,"prevYearClose":0.17,"prevWeekClose":0.11,"prevMonthClose":0.105,"prevQuarterClose":0.125,"fiveDayClose":0.11,"twentyDayClose":0.11,"sixtyDayClose":0.125,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2578697763","title":"Securities Trading Policy-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578697763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578697763?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:16","pubTimestamp":1761549382,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX2wd2by","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX71hzHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2578697239","title":"Constitution-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578697239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578697239?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:14","pubTimestamp":1761549259,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX27Q9b4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX9ntwGv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2578069754","title":"Golden Dragon Mining Ltd FY2023 Audited Accounts-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578069754","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578069754?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:04","pubTimestamp":1761548690,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX6rJrfn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASXSyJVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2578969233","title":"Neurizon Therapeutics Ltd-Replacement Prospectus-Gdr","url":"https://stock-news.laohu8.com/highlight/detail?id=2578969233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578969233?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:01","pubTimestamp":1761548497,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUE8J8KKM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2578862697","title":"Replacement Prospectus-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578862697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578862697?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:01","pubTimestamp":1761548492,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX4HbTrg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASXc8wBgZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2578692900","title":"Information Form and Checklist-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578692900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578692900?lang=en_us&edition=fundamental","pubTime":"2025-10-27 14:48","pubTimestamp":1761547718,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX3n2fh0","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX7nW6Lc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2578949136","title":"Appendix 1A-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578949136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578949136?lang=en_us&edition=fundamental","pubTime":"2025-10-27 14:23","pubTimestamp":1761546212,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX8k9cL7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX2h0P1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2578699740","title":"ASX Market Announcement - Admission and Quotation-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578699740","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578699740?lang=en_us&edition=fundamental","pubTime":"2025-10-27 13:38","pubTimestamp":1761543513,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX2bMVjN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX4ZBYNw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2577846313","title":"Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577846313","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577846313?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:33","pubTimestamp":1761028406,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  was told by the Australian Patent Office of the grant of a new method of use patent, which will extend protection for its NUZ-001 drug candidate and related compounds across key therapeutic areas, including mTOR-pathway related diseases, such as amyotrophic lateral sclerosis, and other neurodegenerative diseases, according to a Tuesday Australian bourse filing.The granted patent complements Neurizon's existing US patent for NUZ-001 in neurodegenerative diseases and cancer and gives the firm unified intellectual property protection through to May 2041 across major global markets, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK7096","XKO.AU","BK4539","XJO.AU","XAO.AU","NUZ.AU","BK4007"],"gpt_icon":0},{"id":"2576882786","title":"Neurizon Therapeutics Ltd-Quarterly Shareholder Update Webinar - Q1 FY2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2576882786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576882786?lang=en_us&edition=fundamental","pubTime":"2025-10-20 13:17","pubTimestamp":1760937451,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUE8VFPY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2573262453","title":"BRIEF-FDA Lifts Clinical Hold On Nuz-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2573262453","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573262453?lang=en_us&edition=fundamental","pubTime":"2025-10-06 14:35","pubTimestamp":1759732546,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Lifts Clinical Hold On Nuz-001Oct 6 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:FDA LIFTS CLINICAL HOLD ON NUZ-001NEURIZON THERAPEUTICS LTD: CLEARS WAY FOR ENTRY INTO HEALEY ALS PLATFORM TR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA8SP9MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2573621664","title":"Neurizon Therapeutics Ltd: Clears Way for Entry Into Healey ALS Platform Trial Expected to Commence in Q4 Cy2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573621664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573621664?lang=en_us&edition=fundamental","pubTime":"2025-10-06 14:06","pubTimestamp":1759730807,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA8SP9MV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2573644556","title":"BUZZ-Neurizon Therapeutics rises after US FDA lifts clinical hold on key therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2573644556","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573644556?lang=en_us&edition=fundamental","pubTime":"2025-10-06 07:51","pubTimestamp":1759708301,"startTime":"0","endTime":"0","summary":"BUZZ-Neurizon Therapeutics rises after US FDA lifts clinical hold on key therapy** Shares of Australia's Neurizon Therapeutics NUZ.AX rise as much as 13.8% to A$0.165, their highest level since August 27** Stock on track for a second consecutive session of gains, if trend holds** Biotechnology co says the U.S. Food and Drug Administration  has lifted clinical hold on NUZ-001, its lead investigational therapy for advancing innovative treatments for neurodegenerative diseases** Nearly 2.7 mln shares change hands, 3.5x the 30-day average volume ** Stock has fallen 11.8% so far this year   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251005:nL3N3VM04U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2573467536","title":"Neurizon Therapeutics Ltd - U.S. FDA Lifts Clinical Hold on Nuz-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2573467536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573467536?lang=en_us&edition=fundamental","pubTime":"2025-10-06 05:55","pubTimestamp":1759701349,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251005:nFWN3VK0CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2572885658","title":"Neurizon Therapeutics' (ASX:NUZ) growing losses don't faze investors as the stock spikes 12% this past week","url":"https://stock-news.laohu8.com/highlight/detail?id=2572885658","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572885658?lang=en_us&edition=fundamental","pubTime":"2025-10-04 06:32","pubTimestamp":1759530721,"startTime":"0","endTime":"0","summary":"By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/neurizon-therapeutics-asxnuz-growing-losses-dont-faze-invest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/neurizon-therapeutics-asxnuz-growing-losses-dont-faze-invest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2568342646","title":"Neurizon Therapeutics Secures AU$5 Million Through Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2568342646","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568342646?lang=en_us&edition=fundamental","pubTime":"2025-09-18 14:39","pubTimestamp":1758177595,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  has secured firm commitments to raise AU$5 million through a placement of 43.3 million shares priced at AU$0.12 each, reflecting an 18.9% discount to the recent five-day volume weighted average price, according to a Thursday filing with the Australian bourse.The board and management have committed to subscribe for an additional AU$200,000 under the placement, with AU$130,000 requiring shareholder approval at the annual general meeting around Nov. 26, per the filing.Settlement is anticipated on Sept. 23, with shares to be allotted soon thereafter, the filing said.Funds will support the company's planned entry into the HEALEY ALS platform trial, subject to US Food and Drug Administration clearance, as well as the manufacturing of GMP batches, regulatory filings, pre-clinical research, and general working capital, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","NUZ.AU","BK4539","BK7096","BK4139","BK4007"],"gpt_icon":0},{"id":"2568443893","title":"Neurizon Therapeutics - Raises a$5 Mln via Institutional Placement at a$0.12 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2568443893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568443893?lang=en_us&edition=fundamental","pubTime":"2025-09-18 07:25","pubTimestamp":1758151559,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nFWN3V40VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2567124643","title":"BRIEF-Neurizon Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2567124643","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567124643?lang=en_us&edition=fundamental","pubTime":"2025-09-16 09:38","pubTimestamp":1757986720,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Seeks Trading HaltSept 16 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:SEEKS TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V20J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2562627713","title":"BRIEF-Neurizon Therapeutics Posts Loss For Year Attributable A$16.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562627713","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562627713?lang=en_us&edition=fundamental","pubTime":"2025-08-26 09:32","pubTimestamp":1756171921,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Posts Loss For Year Attributable A$16.6 MillionAug 26 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:LOSS FOR YEAR ATTRIBUTABLE A$16.6 MILLIONFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UH0NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2562356279","title":"Neurizon Therapeutics - Loss for Year Attributable a$16.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562356279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562356279?lang=en_us&edition=fundamental","pubTime":"2025-08-26 07:35","pubTimestamp":1756164930,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":52,"code":"91000000","status":"200"}]}}